Surrogate Endpoint

Understanding Surrogate Endpoints

Core Concept

Aspect	Description
What it is	Measurable biological marker
What it predicts	Clinical outcome (how patient feels/survives)
Why used	Faster measurement than clinical endpoints
Limitation	Prediction may not always be accurate

The Surrogate-Outcome Relationship

Drug → Surrogate Endpoint → Clinical Outcome
        (measurable)        (what matters)

Example:
Drug → LDL Reduction → Fewer Heart Attacks
       (measured)      (predicted)

Validation Levels

FDA Classifications

Level	Definition	Regulatory Use
Validated surrogate	Demonstrated prediction of clinical benefit	Standard approval
Reasonably likely surrogate	Substantial evidence supports prediction	Accelerated approval
Candidate surrogate	Plausible but unproven relationship	Research only

What Validation Requires

• Biological plausibility (mechanism makes sense)
• Consistent correlation with clinical outcomes
• Evidence that changing surrogate changes outcome
• Confirmation across multiple studies

Common Surrogate Endpoints

Metabolic Disease

Surrogate	Predicts	Validation Status
HbA1c	Diabetic complications	Well-validated
LDL cholesterol	Cardiovascular events	Validated
Blood pressure	Stroke, heart disease	Validated
Body weight	Cardiometabolic risk	Reasonably likely

Oncology

Surrogate	Predicts	Validation Status
Tumor response	Survival	Varies by cancer
Progression-free survival	Overall survival	Partial in some cancers
Pathologic complete response	Long-term outcomes	Reasonably likely (some)

Surrogate Endpoints in Peptide Trials

GLP-1 Agonist Development

Diabetes Approval:

• Primary surrogate: HbA1c reduction
• Well-validated for diabetic complications
• Accepted for standard approval

Obesity Approval:

• Primary surrogate: Body weight reduction
• Reasonably likely to predict cardiometabolic benefit
• Cardiovascular outcome trials required/conducted

Key Trial Examples

Trial	Drug	Surrogate Used	Clinical Confirmation
SUSTAIN	Semaglutide	HbA1c	SUSTAIN-6 (MACE)
SURPASS	Tirzepatide	HbA1c, weight	SURPASS-CVOT (ongoing)
STEP	Semaglutide	Weight loss	SELECT trial (MACE confirmed)

Benefits of Surrogate Endpoints

Advantages for Drug Development

Benefit	Explanation
Faster trials	Weeks/months vs years
Smaller trials	Hundreds vs thousands of patients
Lower cost	Millions vs billions of dollars
Earlier access	Patients get drugs sooner

When Surrogates Work Well

• Strong biological relationship to outcome
• Extensive validation across multiple studies
• Surrogate lies on causal pathway to outcome
• Historical experience confirms prediction

Limitations and Failures

When Surrogates Mislead

Example	Surrogate	Expected	Actual
CETP inhibitors	HDL increase	Fewer heart attacks	No benefit or harm
Fluoride for bones	Bone density	Fewer fractures	More fractures
Encainide/flecainide	Arrhythmia suppression	Fewer deaths	More deaths

Why Surrogates Can Fail

• Drug affects surrogate but not outcome (off-pathway effect)
• Drug has harmful effects not captured by surrogate
• Surrogate-outcome relationship varies by mechanism
• Different populations have different relationships

Regulatory Requirements

Accelerated Approval Pathway

When drugs are approved on surrogate endpoints:

Requirement	Purpose
Post-marketing trials	Confirm clinical benefit
Due diligence	Complete trials promptly
Ongoing assessment	FDA monitors for signals
Potential withdrawal	If benefit not confirmed

Recent FDA Enforcement

FDA has increased scrutiny of accelerated approvals:

• Required completion of confirmatory trials
• Withdrawn approvals when trials failed
• Enforced faster timelines for post-marketing studies

Interpreting Surrogate Data

Questions to Ask

Question	Why It Matters
How validated is the surrogate?	Determines reliability of prediction
What’s the effect size?	Small surrogate changes may not be meaningful
Are clinical outcome trials planned?	Will prediction be confirmed?
What’s the mechanism?	Is surrogate on causal pathway?

Effect Size Considerations

Not all surrogate changes are clinically meaningful:

Surrogate	Clinically Meaningful Change
HbA1c	0.5% or greater reduction
LDL-C	30%+ reduction (varies by baseline)
Body weight	5%+ reduction typically meaningful
Blood pressure	5-10 mmHg systolic

Frequently Asked Questions

Why not always require clinical endpoints?

Clinical endpoint trials can take 5+ years and cost billions of dollars. For serious conditions with unmet needs, waiting for definitive outcomes would delay patient access. Surrogates enable faster access while confirmatory studies continue.

How do I know if a surrogate is trustworthy?

Look for: extensive validation history, biological plausibility, FDA acceptance for approval, and ideally confirmation from outcome trials with similar drugs. Well-validated surrogates like HbA1c and LDL have decades of supporting evidence.

What does “reasonably likely to predict” mean?

FDA uses this standard for accelerated approval. It means substantial evidence supports the surrogate-outcome relationship, but it’s not definitively proven for the specific drug. Post-approval clinical endpoint trials are required to confirm.

Can surrogate endpoint results be misleading?

Yes. History shows examples where improving a surrogate didn’t improve—or even worsened—clinical outcomes. This is why clinical endpoint confirmation remains important and why FDA monitors accelerated approvals closely.